7.54 USD
-0.24 (-3.08%)
At close: Jan 30, 2026
7.62 USD
+0.08 (+1.06%)
After Hours: 1/30/2026, 8:23:29 PM
Overall VNDA gets a fundamental rating of 2 out of 10. We evaluated VNDA against 525 industry peers in the Biotechnology industry. While VNDA is still in line with the averages on profitability rating, there are concerns on its financial health. VNDA has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- VNDA had negative earnings in the past year.
- VNDA had a negative operating cash flow in the past year.
- Of the past 5 years VNDA 4 years were profitable.
- VNDA had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
- VNDA's Return On Assets of -14.01% is amongst the best of the industry. VNDA outperforms 80.76% of its industry peers.
- VNDA's Return On Equity of -18.07% is amongst the best of the industry. VNDA outperforms 84.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.01% | ||
| ROE | -18.07% | ||
| ROIC | N/A |
ROA(3y)-0.5%
ROA(5y)1.69%
ROE(3y)-0.62%
ROE(5y)1.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Gross Margin of VNDA (94.44%) is better than 95.05% of its industry peers.
- VNDA's Gross Margin has been stable in the last couple of years.
- The Profit Margin and Operating Margin are not available for VNDA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 94.44% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.39%
GM growth 5Y1.12%
2. Health
2.1 Basic Checks
- VNDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
- VNDA has more shares outstanding than it did 1 year ago.
- VNDA has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for VNDA is higher compared to a year ago.
2.2 Solvency
- VNDA has an Altman-Z score of 1.57. This is a bad value and indicates that VNDA is not financially healthy and even has some risk of bankruptcy.
- VNDA has a Altman-Z score of 1.57. This is in the better half of the industry: VNDA outperforms 65.71% of its industry peers.
- VNDA has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
- Looking at the Debt to Equity ratio, with a value of 0.01, VNDA is in line with its industry, outperforming 46.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.57 |
ROIC/WACCN/A
WACC8.87%
2.3 Liquidity
- VNDA has a Current Ratio of 3.12. This indicates that VNDA is financially healthy and has no problem in meeting its short term obligations.
- VNDA has a worse Current ratio (3.12) than 62.86% of its industry peers.
- VNDA has a Quick Ratio of 3.10. This indicates that VNDA is financially healthy and has no problem in meeting its short term obligations.
- With a Quick ratio value of 3.10, VNDA is not doing good in the industry: 60.57% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.12 | ||
| Quick Ratio | 3.1 |
3. Growth
3.1 Past
- VNDA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -407.14%.
- Looking at the last year, VNDA shows a quite strong growth in Revenue. The Revenue has grown by 11.12% in the last year.
- Measured over the past years, VNDA shows a decrease in Revenue. The Revenue has been decreasing by -2.64% on average per year.
EPS 1Y (TTM)-407.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-322.22%
Revenue 1Y (TTM)11.12%
Revenue growth 3Y-9.56%
Revenue growth 5Y-2.64%
Sales Q2Q%18.06%
3.2 Future
- The Earnings Per Share is expected to decrease by -33.71% on average over the next years. This is quite bad
- Based on estimates for the next years, VNDA will show a small growth in Revenue. The Revenue will grow by 1.13% on average per year.
EPS Next Y-751.86%
EPS Next 2Y-114.8%
EPS Next 3Y-33.71%
EPS Next 5YN/A
Revenue Next Year9.44%
Revenue Next 2Y16.63%
Revenue Next 3Y20.31%
Revenue Next 5Y1.13%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for VNDA. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VNDA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as VNDA's earnings are expected to decrease with -33.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-114.8%
EPS Next 3Y-33.71%
5. Dividend
5.1 Amount
- VNDA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
VANDA PHARMACEUTICALS INC / VNDA FAQ
What is the ChartMill fundamental rating of VANDA PHARMACEUTICALS INC (VNDA) stock?
ChartMill assigns a fundamental rating of 2 / 10 to VNDA.
What is the valuation status of VANDA PHARMACEUTICALS INC (VNDA) stock?
ChartMill assigns a valuation rating of 0 / 10 to VANDA PHARMACEUTICALS INC (VNDA). This can be considered as Overvalued.
What is the profitability of VNDA stock?
VANDA PHARMACEUTICALS INC (VNDA) has a profitability rating of 4 / 10.
Can you provide the financial health for VNDA stock?
The financial health rating of VANDA PHARMACEUTICALS INC (VNDA) is 3 / 10.
What is the expected EPS growth for VANDA PHARMACEUTICALS INC (VNDA) stock?
The Earnings per Share (EPS) of VANDA PHARMACEUTICALS INC (VNDA) is expected to decline by -751.86% in the next year.